Treatment of Liver Cirrhosis

Core Treatment Principles

The American College of Cardiology is not mentioned, however, the fundamental treatment difference is that complete alcohol abstinence is the single most critical intervention for alcoholic cirrhosis—improving survival from 0% to 75% at 3 years—while non-alcoholic cirrhosis requires aggressive management of metabolic comorbidities including weight loss, diabetes control, and cardiovascular risk reduction 1, 2
Alcohol abstinence is non-negotiable and represents the most effective intervention across all stages of disease, with stopping alcohol able to reverse the reversible component of liver disease and dramatically improve response to medical therapy, even in advanced cirrhosis 1, 2, 3
Persistence of alcohol abuse is the most important factor increasing risk of complications and death, and even moderate alcohol consumption worsens portal hypertension and precipitates clinical decompensation 2, 3
Pharmacologic support for abstinence should avoid disulfiram due to hepatotoxicity, and consider baclofen as a safe anti-craving medication in advanced liver disease 1, 3
Nutritional management is critical as malnutrition affects up to 50% of alcoholic liver disease patients, with aggressive nutritional therapy, frequent interval feedings, emphasis on nighttime snack and morning feeding, adequate protein intake of 1.2-1.5 g/kg/day, and consideration of enteral nutrition if oral intake is significantly compromised 1, 3

Lifestyle modifications and metabolic disease management form the cornerstone of treatment for all NAFLD patients, regardless of fibrosis stage, with weight reduction, dietary control, and exercise applied to all NAFLD patients, and obesity associated with both liver fibrosis and HCC development 4
Weight loss improves both steatosis and fibrosis, and metabolic comorbidity management should treat diabetes, obesity, hypertension, and dyslipidemia aggressively, with metformin decreasing HCC incidence, and statin use reducing HCC risk by 37% in meta-analyses 4
Pharmacologic treatment is selective, reserved for patients with NASH or hepatic fibrosis (≥F2), as these patients have worse long-term prognosis, and fibrosis stage ≥F2 is an independent predictor of liver-related complications and mortality 4

Ascites management should restrict sodium intake to 88 mmol/day, start spironolactone 100 mg once daily, add furosemide 40 mg once daily if needed, with maximum doses of 400 mg/day spironolactone and 160 mg/day furosemide, and fluid restriction only necessary if serum sodium <120-125 mmol/L 1, 2
For tense ascites, perform large-volume paracentesis, and administer intravenous albumin at 8g/L of fluid removed to prevent circulatory dysfunction, with critical pitfall being avoidance of NSAIDs as they reduce urinary sodium excretion and can convert diuretic-sensitive patients to refractory 2
HCC surveillance is necessary for both alcoholic and non-alcoholic cirrhosis, with annual HCC incidence approximately 2.6% in alcoholic cirrhosis, and patients with NAFLD-related cirrhosis requiring HCC surveillance, using abdominal ultrasound as primary surveillance test, but CT or MRI in overweight/obese patients where ultrasound is difficult 3, 4
Hepatic encephalopathy has the highest mortality among decompensated cirrhosis complications in both types, and identification and treatment of precipitants is crucial, with lactulose or rifaximin used to reduce serum ammonia levels 1, 3

Alcoholic cirrhosis prognosis is heavily dependent on continued drinking, with 75% 3-year survival with abstinence vs 0% with continued drinking, and development of ascites indicating poor prognosis with approximately 20% mortality within first year 2
Non-alcoholic cirrhosis prognosis relates to fibrosis severity, with fibrosis stage being the most important histologic marker for long-term prognosis, and presence of steatohepatitis accelerating fibrosis progression 4

Both types require caution with paracetamol, particularly when malnourished, and are at increased risk for bacterial infections requiring prompt antibiotic therapy, with avoidance of medications that worsen hypotension (ACE inhibitors) in both types 1, 2, 3